Literature DB >> 18436227

Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease.

Aaron R Folsom1, James M Peacock, Eric Boerwinkle.   

Abstract

BACKGROUND: We hypothesized that variants in PCSK9 that lower LDL cholesterol levels are associated with reduced prevalence and incidence of peripheral artery disease (PAD).
METHODS: The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634). Prevalent PAD (n=619 cases) was defined by an ankle-brachial index <0.9 or a history of leg claudication. Incident PAD (n=895) was identified from 1987 to 1998 by the same PAD criteria or a PAD hospitalization.
RESULTS: As expected, greater LDL cholesterol was a risk factor for prevalent and incident PAD. 2.4% of blacks and 3.1% of whites were carriers of one of the race-specific PCSK9 variants. Carriers had lower prevalence of PAD compared with non-carriers (2.3% vs. 4.6%). The corresponding age- and sex-adjusted odds ratio of PAD was 0.47 (95% confidence interval, 0.24-0.92). In contrast with the cross-sectional findings, there was no association between PCSK9 variants and incident PAD (age- and sex-adjusted hazard ratio, 1.09 (95% confidence interval, 0.76-1.57)).
CONCLUSIONS: Our study provides mixed evidence that variation in PCSK9 may contribute to genetic risk of PAD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436227      PMCID: PMC2607475          DOI: 10.1016/j.atherosclerosis.2008.03.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  15 in total

Review 1.  Critical issues in peripheral arterial disease detection and management: a call to action.

Authors:  Jill J F Belch; Eric J Topol; Giancarlo Agnelli; Michel Bertrand; Robert M Califf; Denis L Clement; Mark A Creager; J Donald Easton; James R Gavin; Philip Greenland; Graeme Hankey; Peter Hanrath; Alan T Hirsch; Jürgen Meyer; Sidney C Smith; Frank Sullivan; Michael A Weber
Journal:  Arch Intern Med       Date:  2003-04-28

2.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

Review 3.  Intermittent claudication: a condition with underrated risks.

Authors:  J Dormandy; L Heeck; S Vig
Journal:  Semin Vasc Surg       Date:  1999-06       Impact factor: 1.000

Review 4.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

Authors:  Jonathan Cohen; Alexander Pertsemlidis; Ingrid K Kotowski; Randall Graham; Christine Kim Garcia; Helen H Hobbs
Journal:  Nat Genet       Date:  2005-01-16       Impact factor: 38.330

7.  The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.

Authors:  Amanda J Hooper; A David Marais; Donald M Tanyanyiwa; John R Burnett
Journal:  Atherosclerosis       Date:  2006-09-20       Impact factor: 5.162

8.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

9.  Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study).

Authors:  D Michael Hallman; Sathanur R Srinivasan; Wei Chen; Eric Boerwinkle; Gerald S Berenson
Journal:  Am J Cardiol       Date:  2007-05-11       Impact factor: 2.778

10.  The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.

Authors:  Marileia Scartezini; Christina Hubbart; Ros A Whittall; Jackie A Cooper; Andrew H W Neil; Steve E Humphries
Journal:  Clin Sci (Lond)       Date:  2007-12       Impact factor: 6.124

View more
  12 in total

1.  ABO blood group is associated with peripheral arterial disease in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mindy M Pike; Nicholas B Larson; Christina L Wassel; Kevin P Cohoon; Michael Y Tsai; James S Pankow; Naomi Q Hanson; Paul A Decker; Cecilia Berardi; Kristine S Alexander; Mary Cushman; Neil A Zakai; Suzette J Bielinski
Journal:  Thromb Res       Date:  2017-02-24       Impact factor: 3.944

Review 2.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

Review 3.  The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.

Authors:  Jean Davignon; Geneviève Dubuc; Nabil G Seidah
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

4.  Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study.

Authors:  Deepak K Gupta; Amil M Shah; Davide Castagno; Madoka Takeuchi; Laura R Loehr; Ervin R Fox; Kenneth R Butler; Thomas H Mosley; Dalane W Kitzman; Scott D Solomon
Journal:  JACC Heart Fail       Date:  2013-04       Impact factor: 12.035

5.  Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.

Authors:  Hong-mei Gu; Ayinuer Adijiang; Matthew Mah; Da-wei Zhang
Journal:  J Lipid Res       Date:  2013-10-08       Impact factor: 5.922

6.  Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities).

Authors:  Deepak K Gupta; Hicham Skali; Brian Claggett; Rumen Kasabov; Susan Cheng; Amil M Shah; Laura R Loehr; Gerardo Heiss; Vijay Nambi; David Aguilar; Lisa Miller Wruck; Kunihiro Matsushita; Aaron R Folsom; Wayne D Rosamond; Scott D Solomon
Journal:  JACC Heart Fail       Date:  2014-09-03       Impact factor: 12.035

7.  PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population.

Authors:  Iris Postmus; Stella Trompet; Anton J M de Craen; Brendan M Buckley; Ian Ford; David J Stott; Naveed Sattar; P Eline Slagboom; Rudi G J Westendorp; J Wouter Jukema
Journal:  J Lipid Res       Date:  2013-02       Impact factor: 5.922

8.  Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.

Authors:  Dengfeng Han; Jianhua Ma; Xiaoning Zhang; Jian Cai; Jinlan Li; Tuerhong Tuerxun; Chenguang Hao; Lei Du; Jing Lei
Journal:  Med Sci Monit       Date:  2014-09-30

Review 9.  Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Authors:  Marianne Abifadel; Sandy Elbitar; Petra El Khoury; Youmna Ghaleb; Mélody Chémaly; Marie-Line Moussalli; Jean-Pierre Rabès; Mathilde Varret; Catherine Boileau
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.967

10.  LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.

Authors:  Eguzkine Ochoa; Mikel Iriondo; Carmen Manzano; Asier Fullaondo; Irama Villar; Guillermo Ruiz-Irastorza; Ana M Zubiaga; Andone Estonba
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.